Stock Research: Sawai Pharmaceutical

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Sawai Pharmaceutical

TSE:4555 JP3323040000
58
  • Value
    59
  • Growth
    44
  • Safety
    Safety
    88
  • Combined
    81
  • Sentiment
    34
  • 360° View
    360° View
    58
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Sawai Group Holdings Co Ltd manufactures and sells medical and over-the-counter drugs. They operate in pharmaceutical and medical device manufacturing and sales, and R&D. Key regions include Japan and America. In the last fiscal year, the company had 3310 employees, a market cap of $1489 million, profits of $376 million, and revenue of $1261 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 58 (better than 58% compared with alternatives), overall professional sentiment and financial characteristics for the stock Sawai Pharmaceutical are above average. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Sawai Pharmaceutical. The consolidated Value Rank has an attractive rank of 88, which means that the share price of Sawai Pharmaceutical is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 88% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 59. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 34. Professional investors are more confident in 66% other stocks. The consolidated Growth Rank also has a low rank of 44, which means that the company is below average in terms of growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. 56 of its competitors have better growth. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 16-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
88 86 92 100
Growth
44 59 39 51
Safety
Safety
59 61 72 70
Sentiment
34 86 82 25
360° View
360° View
58 98 98 87
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
47 40 44 28
Opinions Change
50 70 82 50
Pro Holdings
n/a 92 82 39
Market Pulse
64 65 54 44
Sentiment
34 86 82 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
88 86 92 100
Growth
44 59 39 51
Safety Safety
59 61 72 70
Combined
81 86 92 94
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
83 81 74 97
Price vs. Earnings (P/E)
79 76 91 97
Price vs. Book (P/B)
67 78 71 93
Dividend Yield
72 65 82 92
Value
88 86 92 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
51 36 37 43
Profit Growth
23 79 50 81
Capital Growth
57 34 18 24
Stock Returns
56 74 77 49
Growth
44 59 39 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
23 27 33 36
Refinancing
76 76 89 89
Liquidity
61 59 59 53
Safety Safety
59 61 72 70

Similar Stocks

Discover high‑ranked alternatives to Sawai Pharmaceutical and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Starts

TSE:8850
Country: Japan
Industry: Real Estate: Diversified Operations
Size: Medium
Full Stock Analysis

Daiwabo Holdings

TSE:3107
Country: Japan
Industry: Technology Distributors
Size: Medium
Full Stock Analysis

Nagase

TSE:8012
Country: Japan
Industry: Trading & Distribution
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.